GSK Acquires Elsie Biotechnologies to Advance Oligonucleotide Therapeutics for Liver Diseases and Beyond

Jun 07, 2024 07:51 CST Updated 07:51

GSK

Pharmaceutical R&D Manufacturer

Elsie Biotechnologies

Oligonucleotide Therapy Developer

June 6,GSKGSK Announces Acquisition of Elsie Biotechnologies for Up to $50 Million (£39 Million). This acquisition integrates Elsie's oligonucleotide discovery, synthesis, and delivery technologies to enhance GSK's R&D capabilities. Prior to this, GSK had established a research collaboration with Elsie in July 2023.

Data generated based on the Elsie platform, combined with GSK's expertise in artificial intelligence and machine learning, will support the development of predictive models for future oligonucleotide drug design.

Oligonucleotides have the unique ability to regulate gene expression, making them an attractive approach to addressing a large proportion of therapeutic targets that cannot be tackled by traditional small molecules or biologics.

This acquisition aligns with GSK's approach of combining science and technology, including advancing novel platform technologies to accelerate drug development, ultimately delivering innovative medicines to patients better and faster. GSK is currently advancing oligonucleotide therapies for chronic hepatitis B and fatty liver disease, as well as other therapeutic areas beyond liver diseases.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content in this article.